Press Release
-
Phase 1 Sigle Ascending Dose Clinical Trail in 42 Health Volunteers2022-07-01A total number of 42 subjects were randomized into the Phase 1a single ascending dose (SAD) study. The data exhibit good safety profile of PSP001. No serious treatment-emergent adverse events in the 42 subjects were noted.
-
Prosit Sole had initiated the first-in-human (“FIH”) Phase I clinical trial of PSP001 in US2021-05-28Baltimore, USA, May26,2021&/--PrositSole Biotechnology, a clinical-stage biotech company developing novel protein therapeutics, today announces that it has initiated the FIH clinical trial of PSP001 in the US.
